DK168061B1 - Med mrna hybridiserbart anti-viralt middel - Google Patents

Med mrna hybridiserbart anti-viralt middel Download PDF

Info

Publication number: DK168061B1
Authority: DK; Denmark
Prior art keywords: dna; virus; mrna; cells; hsv
Prior art date: 1983-10-17

Application number

DK493584A

Other languages

Danish (da)

English (en)

Other versions

DK493584D0 (da

DK493584A (da

Inventor

Akira Kaji

Original Assignee

Akira Kaji

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-10-17

Filing date

1984-10-16

Publication date

1994-01-31

1983-10-17 Priority claimed from JP58192350A external-priority patent/JPH0740934B2/ja

1984-03-16 Priority claimed from JP59049321A external-priority patent/JPS60193922A/ja

1984-10-16 Application filed by Akira Kaji filed Critical Akira Kaji

1984-10-16 Publication of DK493584D0 publication Critical patent/DK493584D0/da

1985-04-18 Publication of DK493584A publication Critical patent/DK493584A/da

1994-01-31 Application granted granted Critical

1994-01-31 Publication of DK168061B1 publication Critical patent/DK168061B1/da

Links

108020004999 messenger RNA Proteins 0.000 title claims description 56
239000003443 antiviral agent Substances 0.000 title description 16
241000700605 Viruses Species 0.000 claims description 47
229940046166 oligodeoxynucleotide Drugs 0.000 claims description 47
241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 35
239000000243 solution Substances 0.000 claims description 34
241000700584 Simplexvirus Species 0.000 claims description 29
238000002347 injection Methods 0.000 claims description 24
239000007924 injection Substances 0.000 claims description 24
239000000203 mixture Substances 0.000 claims description 23
108090000623 proteins and genes Proteins 0.000 claims description 23
239000002773 nucleotide Substances 0.000 claims description 13
125000003729 nucleotide group Chemical group 0.000 claims description 13
238000002360 preparation method Methods 0.000 claims description 13
230000000840 anti-viral effect Effects 0.000 claims description 7
241001529453 unidentified herpesvirus Species 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
239000003889 eye drop Substances 0.000 claims description 3
229940012356 eye drops Drugs 0.000 claims 1
108020004414 DNA Proteins 0.000 description 125
210000004027 cell Anatomy 0.000 description 60
238000002474 experimental method Methods 0.000 description 42
241000699670 Mus sp. Species 0.000 description 35
230000015572 biosynthetic process Effects 0.000 description 21
230000014616 translation Effects 0.000 description 18
108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
238000000034 method Methods 0.000 description 17
238000003786 synthesis reaction Methods 0.000 description 16
230000000694 effects Effects 0.000 description 15
230000005764 inhibitory process Effects 0.000 description 14
230000002401 inhibitory effect Effects 0.000 description 12
102000053602 DNA Human genes 0.000 description 11
241000699666 Mus <mouse, genus> Species 0.000 description 11
239000002253 acid Substances 0.000 description 11
239000003814 drug Substances 0.000 description 11
230000035755 proliferation Effects 0.000 description 11
102100027685 Hemoglobin subunit alpha Human genes 0.000 description 10
108091005902 Hemoglobin subunit alpha Proteins 0.000 description 10
108091028043 Nucleic acid sequence Proteins 0.000 description 10
229940079593 drug Drugs 0.000 description 10
241001493065 dsRNA viruses Species 0.000 description 10
238000000338 in vitro Methods 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
241001524679 Escherichia virus M13 Species 0.000 description 9
208000015181 infectious disease Diseases 0.000 description 9
239000002609 medium Substances 0.000 description 9
238000001243 protein synthesis Methods 0.000 description 9
238000013519 translation Methods 0.000 description 9
239000013598 vector Substances 0.000 description 9
230000000120 cytopathologic effect Effects 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
241000712461 unidentified influenza virus Species 0.000 description 8
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 7
108091026890 Coding region Proteins 0.000 description 7
239000011575 calcium Substances 0.000 description 7
210000004671 cell-free system Anatomy 0.000 description 7
239000007788 liquid Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
241000588724 Escherichia coli Species 0.000 description 6
108020005202 Viral DNA Proteins 0.000 description 6
108700005077 Viral Genes Proteins 0.000 description 6
239000001963 growth medium Substances 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
235000018102 proteins Nutrition 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
230000017960 syncytium formation Effects 0.000 description 6
102100021519 Hemoglobin subunit beta Human genes 0.000 description 5
108091005904 Hemoglobin subunit beta Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
108020004682 Single-Stranded DNA Proteins 0.000 description 5
239000000654 additive Substances 0.000 description 5
239000003242 anti bacterial agent Substances 0.000 description 5
229940088710 antibiotic agent Drugs 0.000 description 5
244000309466 calf Species 0.000 description 5
239000000969 carrier Substances 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
108010039177 polyphenylalanine Proteins 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
239000000725 suspension Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
229930182555 Penicillin Natural products 0.000 description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
238000007792 addition Methods 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
229940049954 penicillin Drugs 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
229960005322 streptomycin Drugs 0.000 description 4
239000000829 suppository Substances 0.000 description 4
150000005691 triesters Chemical class 0.000 description 4
229920001817 Agar Polymers 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
241000450599 DNA viruses Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
108700002232 Immediate-Early Genes Proteins 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
108010067390 Viral Proteins Proteins 0.000 description 3
239000008272 agar Substances 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000001110 calcium chloride Substances 0.000 description 3
229910001628 calcium chloride Inorganic materials 0.000 description 3
235000011148 calcium chloride Nutrition 0.000 description 3
229910001424 calcium ion Inorganic materials 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
235000011010 calcium phosphates Nutrition 0.000 description 3
210000004087 cornea Anatomy 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
235000013922 glutamic acid Nutrition 0.000 description 3
239000004220 glutamic acid Substances 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
229960004452 methionine Drugs 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
102000016911 Deoxyribonucleases Human genes 0.000 description 2
108010053770 Deoxyribonucleases Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000701959 Escherichia virus Lambda Species 0.000 description 2
101000633984 Homo sapiens Influenza virus NS1A-binding protein Proteins 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
241000209140 Triticum Species 0.000 description 2
235000021307 Triticum Nutrition 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
-1 alkali metal salt Chemical class 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
229960004544 cortisone Drugs 0.000 description 2
239000006196 drop Substances 0.000 description 2
238000012606 in vitro cell culture Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
230000006656 viral protein synthesis Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
235000019737 Animal fat Nutrition 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
SBYQPGZCKZIXFK-UHNVWZDZSA-N CC(C)(O)[C@@H](S)[C@H](O)CO Chemical compound CC(C)(O)[C@@H](S)[C@H](O)CO SBYQPGZCKZIXFK-UHNVWZDZSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
235000005881 Calendula officinalis Nutrition 0.000 description 1
240000001432 Calendula officinalis Species 0.000 description 1
ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
102000004420 Creatine Kinase Human genes 0.000 description 1
108010042126 Creatine kinase Proteins 0.000 description 1
230000007023 DNA restriction-modification system Effects 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
241000490229 Eucephalus Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
241000175212 Herpesvirales Species 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241000712431 Influenza A virus Species 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
101710149086 Nuclease S1 Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
238000010266 Sephadex chromatography Methods 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
239000001639 calcium acetate Substances 0.000 description 1
235000011092 calcium acetate Nutrition 0.000 description 1
229960005147 calcium acetate Drugs 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229960003290 cortisone acetate Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
108091092330 cytoplasmic RNA Proteins 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
235000006694 eating habits Nutrition 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000007373 indentation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
208000037797 influenza A Diseases 0.000 description 1
108700032552 influenza virus INS1 Proteins 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000011285 magnesium acetate Nutrition 0.000 description 1
239000011654 magnesium acetate Substances 0.000 description 1
229940069446 magnesium acetate Drugs 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
231100000255 pathogenic effect Toxicity 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 1
238000002205 phenol-chloroform extraction Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
150000003013 phosphoric acid derivatives Chemical group 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000007790 scraping Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000005727 virus proliferation Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK493584A 1983-10-17 1984-10-16 Med mrna hybridiserbart anti-viralt middel DK168061B1 (da)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
JP19235083		1983-10-17
JP58192350A JPH0740934B2 (ja)	1983-10-17	1983-10-17	ウイルス増殖阻害方法
JP4932184		1984-03-16
JP59049321A JPS60193922A (ja)	1984-03-16	1984-03-16	抗ウイルス剤
MTP957		1984-12-12
MT957A MTP957B (en)	1983-10-17	1984-12-12	Method for inhibiting viral propagation and anti-viral agent

Publications (3)

Publication Number	Publication Date
DK493584D0 DK493584D0 (da)	1984-10-16
DK493584A DK493584A (da)	1985-04-18
DK168061B1 true DK168061B1 (da)	1994-01-31

Family

ID=39877713

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK493584A DK168061B1 (da)	1983-10-17	1984-10-16	Med mrna hybridiserbart anti-viralt middel

Country Status (18)

Country	Link
US (1)	US4689320A (de)
AT (1)	AT392081B (de)
AU (1)	AU578625B2 (de)
BE (1)	BE900827A (de)
CH (1)	CH667593A5 (de)
DE (1)	DE3437852A1 (de)
DK (1)	DK168061B1 (de)
FR (1)	FR2553420B1 (de)
GB (1)	GB2148302B (de)
IE (1)	IE57987B1 (de)
IT (1)	IT1179144B (de)
LU (1)	LU85594A1 (de)
MT (1)	MTP957B (de)
NL (1)	NL8403163A (de)
NZ (1)	NZ209840A (de)
PH (1)	PH21629A (de)
SE (1)	SE466482B (de)
SG (1)	SG31088G (de)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0477994B1 (de) *	1985-03-21	2001-06-13	Johnston, Stephen, Ph.D.	Von Parasit gewonnener Widerstand
US5580716A (en) *	1985-03-21	1996-12-03	Stephen A. Johnston	Parasite-derived resistance
AU612972B2 (en) *	1986-04-02	1991-07-25	Pioneer Hi-Bred International, Inc.	Virus resistant plants having antisense rna
US4806463A (en) *	1986-05-23	1989-02-21	Worcester Foundation For Experimental Biology	Inhibition of HTLV-III by exogenous oligonucleotides
US5194428A (en) *	1986-05-23	1993-03-16	Worcester Foundation For Experimental Biology	Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5637573A (en) *	1986-05-23	1997-06-10	Agrawal; Sudhir	Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions
US5834185A (en) *	1986-10-28	1998-11-10	Johns Hopkins University	Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers which comprise pyrimidine analogs, triple helix complexes formed thereby and oligomers used in their formation
US4904582A (en) *	1987-06-11	1990-02-27	Synthetic Genetics	Novel amphiphilic nucleic acid conjugates
DE68929343T2 (de) *	1988-02-16	2002-09-12	Greatbatch Gen-Aid, Ltd.	Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen
US5004810A (en) *	1988-09-30	1991-04-02	Schering Corporation	Antiviral oligomers
US5098890A (en) *	1988-11-07	1992-03-24	Temple University-Of The Commonwealth System Of Higher Education	Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5693622A (en) *	1989-03-21	1997-12-02	Vical Incorporated	Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
EP0737750B1 (de) *	1989-03-21	2003-05-14	Vical, Inc.	Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US6867195B1 (en) *	1989-03-21	2005-03-15	Vical Incorporated	Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US6214804B1 (en)	1989-03-21	2001-04-10	Vical Incorporated	Induction of a protective immune response in a mammal by injecting a DNA sequence
US6673776B1 (en)	1989-03-21	2004-01-06	Vical Incorporated	Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) *	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
WO1990015814A1 (en) *	1989-06-20	1990-12-27	Meiogenics, Inc.	Nuclease resistant, single-stranded, non-naturally occurring nucleic acid molecules
EP0489846A4 (en) *	1989-09-01	1992-06-24	Temple University Of The Commonwealth System Of Higher Education	Antisense oligonucleotides to c-abl proto-oncogene
ATE162219T1 (de) *	1989-11-16	1998-01-15	Univ Duke	Transformation von tierischen hautzellen mit hilfe von partikeln
US5177198A (en) *	1989-11-30	1993-01-05	University Of N.C. At Chapel Hill	Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5872232A (en) *	1990-01-11	1999-02-16	Isis Pharmaceuticals Inc.	2'-O-modified oligonucleotides
US6399754B1 (en)	1991-12-24	2002-06-04	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides
US6395492B1 (en) *	1990-01-11	2002-05-28	Isis Pharmaceuticals, Inc.	Derivatized oligonucleotides having improved uptake and other properties
US20040142899A1 (en) *	1990-01-11	2004-07-22	Isis Pharmaceuticals, Inc.	Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US5852182A (en) *	1990-01-11	1998-12-22	Isis Pharmaceuticals Inc.	Thiol-derivatized oligonucleosides
US6339066B1 (en)	1990-01-11	2002-01-15	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US6753423B1 (en)	1990-01-11	2004-06-22	Isis Pharmaceuticals, Inc.	Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US7037646B1 (en)	1990-01-11	2006-05-02	Isis Pharmaceuticals, Inc.	Amine-derivatized nucleosides and oligonucleosides
US5859221A (en) *	1990-01-11	1999-01-12	Isis Pharmaceuticals, Inc.	2'-modified oligonucleotides
US6114513A (en) *	1990-01-11	2000-09-05	Isis Pharmaceuticals, Inc.	Thiol-derivatized oligonucleotides
US5459255A (en) *	1990-01-11	1995-10-17	Isis Pharmaceuticals, Inc.	N-2 substituted purines
US6005087A (en) *	1995-06-06	1999-12-21	Isis Pharmaceuticals, Inc.	2'-modified oligonucleotides
HUT63170A (en) *	1990-01-11	1993-07-28	Isis Pharmaceuticals Inc	Process and composition for detecting and modifying rna activity and gene expression
US5248670A (en) *	1990-02-26	1993-09-28	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides for inhibiting herpesviruses
US5514577A (en) *	1990-02-26	1996-05-07	Isis Pharmaceuticals, Inc.	Oligonucleotide therapies for modulating the effects of herpes viruses
US20030186913A1 (en) *	1990-03-21	2003-10-02	Vical Incorporated	Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en)	1991-11-12	2001-05-08	Vical Incorporated	Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6706694B1 (en)	1990-03-21	2004-03-16	Vical Incorporated	Expression of exogenous polynucleotide sequences in a vertebrate
US5610050A (en) *	1990-04-20	1997-03-11	The General Hospital Corporation	Methods of preventing viral replication
US5639595A (en) *	1990-05-01	1997-06-17	Isis Phamaceuticals, Inc.	Identification of novel drugs and reagents
AU7906691A (en) *	1990-05-23	1991-12-10	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Adeno-associated virus (aav)-based eucaryotic vectors
US5135917A (en) *	1990-07-12	1992-08-04	Nova Pharmaceutical Corporation	Interleukin receptor expression inhibiting antisense oligonucleotides
DE69133511T2 (de) *	1990-08-13	2006-09-28	Isis Pharmaceuticals, Inc., Carlsbad	Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression
US6262241B1 (en) *	1990-08-13	2001-07-17	Isis Pharmaceuticals, Inc.	Compound for detecting and modulating RNA activity and gene expression
US5580767A (en) *	1990-08-14	1996-12-03	Isis Pharmaceuticals, Inc.	Inhibition of influenza viruses by antisense oligonucleotides
CA2089476A1 (en) *	1990-08-15	1992-02-16	Bernard Roizman	Inhibition of herpesviridae infection by antisense oligonucleotides
US5595978A (en) *	1990-08-16	1997-01-21	Isis Pharmaceuticals, Inc.	Composition and method for treatment of CMV retinites
AU8872191A (en) *	1990-09-21	1992-04-15	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Method of inhibiting viral production
WO1992005284A1 (en) *	1990-09-21	1992-04-02	University Of Maryland	Compositions and methods for inhibiting growth or replication of viruses
US5942389A (en) *	1990-10-19	1999-08-24	Board Of Trustees Of The University Of Illinois	Genes and genetic elements associated with sensitivity to cisplatin
WO1992013972A1 (en) *	1991-02-11	1992-08-20	Thomas Jefferson University	Genetically engineered bacteria to identify and produce medically important agents
US5965722A (en) *	1991-05-21	1999-10-12	Isis Pharmaceuticals, Inc.	Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
WO1992021353A1 (en) *	1991-05-31	1992-12-10	Genta Incorporated	Compositions and delivery systems for transdermal administration of neutral oligomers
US7119184B2 (en) *	1991-08-12	2006-10-10	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6369209B1 (en)	1999-05-03	2002-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
AU3249793A (en) *	1991-12-24	1993-07-28	Isis Pharmaceuticals, Inc.	Compositions and methods for modulating beta -amyloid
US6033909A (en) *	1992-01-22	2000-03-07	Hoechst Aktiengesellschaft	Oligonucleotide analogs, their preparation and use
US6537973B1 (en)	1992-03-16	2003-03-25	Isis Pharmaceuticals, Inc.	Oligonucleotide inhibition of protein kinase C
US5643780A (en) *	1992-04-03	1997-07-01	Isis Pharmaceuticals, Inc.	Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
US6521601B1 (en) *	1992-04-14	2003-02-18	Signal Pharmaceuticals, Inc.	Method and composition for inhibition of viral replication
US6806084B1 (en) *	1992-06-04	2004-10-19	The Regents Of The University Of California	Methods for compositions for in vivo gene delivery
US6346614B1 (en) *	1992-07-23	2002-02-12	Hybridon, Inc.	Hybrid oligonucleotide phosphorothioates
TW244371B (de) *	1992-07-23	1995-04-01	Tri Clover Inc
AU678769B2 (en) *	1992-07-27	1997-06-12	Hybridon, Inc.	Oligonucleotide alkylphosphonothioates
US5985558A (en) *	1997-04-14	1999-11-16	Isis Pharmaceuticals Inc.	Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
WO1994013303A1 (en) *	1992-12-14	1994-06-23	Start Technology Partnership	Administration of oligonucleotides antisense to dopamine receptor mrna for diagnosis and treatment of neurological pathologies
WO1994017091A2 (en) *	1993-01-21	1994-08-04	Hybridon Inc.	Foldback triplex-forming oligonucleotides
US20040087521A1 (en) *	1993-03-18	2004-05-06	Merck & Co., Inc.	Nucleic acid pharmaceuticals-influenza matrix
KR960704033A (ko) *	1993-07-19	1996-08-31	다니엘 엘. 캐시앙	인간 면역결핍 바이러스에 대한 활성을 갖는 올리고뉴클레오티드(Oligonucleotides with Activity against Humand Immunodeficiency Virus)
US5739309A (en) *	1993-07-19	1998-04-14	Gen-Probe Incorporated	Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
CA2170869C (en)	1993-09-03	1999-09-14	Phillip Dan Cook	Amine-derivatized nucleosides and oligonucleosides
US6653458B1 (en)	1993-09-03	2003-11-25	Isis Pharmaceuticals, Inc.	Modified oligonucleotides
US5837852A (en) *	1993-10-14	1998-11-17	Bristol-Myers Squibb Company	Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease
IL112820A0 (en) *	1994-03-07	1995-05-26	Merck & Co Inc	Coordinate in vivo gene expression
US6995008B1 (en)	1994-03-07	2006-02-07	Merck & Co., Inc.	Coordinate in vivo gene expression
JPH10503364A (ja) *	1994-05-10	1998-03-31	ザジェネラルホスピタルコーポレーション	Ｃ型肝炎ウイルスのアンチセンス阻害
US5733781A (en) *	1994-07-19	1998-03-31	Gen-Probe Incorporated	Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
US5932717A (en) *	1994-09-29	1999-08-03	Asafov; Alexandr V.	Methods of obtaining DNA-RNA hybrids from sturgeon milt
US5750674A (en) *	1995-05-23	1998-05-12	Hybridon, Inc.	Methods and compounds for the stereoselective enrichment of oligonucleotide diastereomers and oligonucleotides thereby produced
US6117993A (en) *	1995-05-23	2000-09-12	Hybridon, Inc.	Synthons for oligonucleotide synthesis
US5693773A (en) *	1995-06-07	1997-12-02	Hybridon Incorporated	Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
US5856099A (en) *	1996-05-21	1999-01-05	Isis Pharmaceuticals, Inc.	Antisense compositions and methods for modulating type I interleukin-1 receptor expression
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US20080119427A1 (en) *	1996-06-06	2008-05-22	Isis Pharmaceuticals, Inc.	Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US5885834A (en) *	1996-09-30	1999-03-23	Epstein; Paul M.	Antisense oligodeoxynucleotide against phosphodiesterase
US6001991A (en) *	1996-10-04	1999-12-14	Isis Pharmaceuticals Inc.	Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US7235653B2 (en) *	1996-12-31	2007-06-26	Isis Pharmaceuticals, Inc.	Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) *	1996-12-31	2000-06-20	Isis Pharmaceuticals, Inc.	Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20040023917A1 (en) *	1996-12-31	2004-02-05	Bennett C. Frank	Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en)	1996-12-31	2001-11-20	Isis Pharmaceuticals	Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO1999001579A1 (en)	1997-07-01	1999-01-14	Isis Pharmaceuticals, Inc.	Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6133246A (en) *	1997-08-13	2000-10-17	Isis Pharmaceuticals Inc.	Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US20070149472A1 (en) *	1997-08-13	2007-06-28	Mckay Robert	Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US5877309A (en) *	1997-08-13	1999-03-02	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides against JNK
US6809193B2 (en)	1997-08-13	2004-10-26	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6306831B1 (en)	1997-09-12	2001-10-23	Qik Technologies, Inc.	Transplacental delivery of oligonucleotides
US6232463B1 (en)	1997-10-09	2001-05-15	Isis Pharmaceuticals, Inc.	Substituted purines and oligonucleotide cross-linking
BRPI9908967B1 (pt) *	1998-03-20	2017-05-30	Benitec Australia Ltd	processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
AUPP249298A0 (en) *	1998-03-20	1998-04-23	Ag-Gene Australia Limited	Synthetic genes and genetic constructs comprising same I
US6841539B1 (en)	1998-05-21	2005-01-11	Isis Pharmaceuticals, Inc.	Compositions and methods for topical delivery of oligonucleotides
WO1999060012A1 (en)	1998-05-21	1999-11-25	Isis Pharmaceuticals, Inc.	Compositions and methods for non-parenteral delivery of oligonucleotides
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6277967B1 (en)	1998-07-14	2001-08-21	Isis Pharmaceuticals, Inc.	Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6242589B1 (en)	1998-07-14	2001-06-05	Isis Pharmaceuticals, Inc.	Phosphorothioate oligonucleotides having modified internucleoside linkages
US6015676A (en) *	1998-07-31	2000-01-18	Epiclone Inc.	Method for knocking out gene transcripts by covalently binding of an anti-sense probe
PT1152009E (pt)	1999-02-12	2005-03-31	Sankyo Co	Novos analogos de nucleosidos e oligonucleotidos
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
JP4151751B2 (ja) *	1999-07-22	2008-09-17	第一三共株式会社	新規ビシクロヌクレオシド類縁体
US6423885B1 (en)	1999-08-13	2002-07-23	Commonwealth Scientific And Industrial Research Organization (Csiro)	Methods for obtaining modified phenotypes in plant cells
US20010011126A1 (en) *	1999-09-10	2001-08-02	Bock Elisabeth Marianne	Neurogenic compositions and methods
US7105962B2 (en) *	2000-08-03	2006-09-12	Matsushita Electric Industrial Co., Ltd.	Brushless motor for partable electronic equipment with wire treatment technique of coils
RU2172632C1 (ru) *	2000-12-01	2001-08-27	Каплина Элли Николаевна	Способ получения иммунотропного противовирусного препарата
RU2188659C1 (ru) *	2001-04-20	2002-09-10	ООО Научно-производственное фармацевтическое предприятие "Полидан"	Фармацевтическая композиция для терапии человека, обладающая иммунотропным действием
US20030096770A1 (en) *	2001-07-11	2003-05-22	Krotz Achim H.	Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
US20030191075A1 (en) *	2002-02-22	2003-10-09	Cook Phillip Dan	Method of using modified oligonucleotides for hepatic delivery
US7704965B2 (en) *	2002-06-26	2010-04-27	The Penn State Research Foundation	Methods and materials for treating human papillomavirus infections
US20040009483A1 (en) *	2002-07-12	2004-01-15	Ilsley Diane D.	Method of linear mRNA amplification using total RNA
WO2004027030A2 (en) *	2002-09-18	2004-04-01	Isis Pharmaceuticals, Inc.	Efficient reduction of target rna’s by single- and double-stranded oligomeric compounds
WO2004043979A2 (en)	2002-11-05	2004-05-27	Isis Pharmaceuticals, Inc.	Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
CA2514912A1 (en) *	2003-02-05	2004-08-26	University Of Massachusetts	Rnai targeting of viruses
WO2004071453A2 (en)	2003-02-13	2004-08-26	Isis Pharmaceuticals, Inc.	Compositions and methods for treatment of pouchitis
US7897582B2 (en) *	2003-05-23	2011-03-01	Isis Pharmaceuticals, Inc.	Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7960355B2 (en) *	2003-05-23	2011-06-14	Isis Pharmaceuticals, Inc.	Compositions and methods for the modulation of the expression of B7 protein
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
JP2010500290A (ja) *	2006-08-04	2010-01-07	アイシスファーマシューティカルズ，インコーポレーテッド	Ｊｎｋタンパク質を調節するための組成物および方法
US20120128673A1 (en)	2009-05-20	2012-05-24	Schering Corporation	Modulation of pilr receptors to treat microbial infections
WO2011084357A1 (en)	2009-12-17	2011-07-14	Schering Corporation	Modulation of pilr to treat immune disorders
EP3868772A1 (de)	2013-09-30	2021-08-25	Geron Corporation	Phosphorodiamidat-rückgratverbindung für oligonukleotide
CN105532575A (zh) *	2016-01-14	2016-05-04	中国科学院昆明动物研究所	一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1107929A (en) *	1965-11-14	1968-03-27	Yissum Res Dev Co	Organotin derivatives of natural and synthetic polymers
JPS5735516A (en) *	1980-08-11	1982-02-26	Yamasa Shoyu Co Ltd	Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
JPS5767518A (en) *	1980-09-17	1982-04-24	Yamasa Shoyu Co Ltd	Radiosensitizing agent or agent for increasing effect of radiomimetic substance
US4511713A (en) *	1980-11-12	1985-04-16	The Johns Hopkins University	Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
US4394443A (en) *	1980-12-18	1983-07-19	Yale University	Method for cloning genes
US4358586A (en) *	1980-12-23	1982-11-09	Harvey Rubin	Detection and isolation of endorphin mRNA using a synthetic oligodeoxynucleotide
DE3106982A1 (de) *	1981-02-25	1982-09-09	Dr. Karl Thomae Gmbh, 7950 Biberach	"neues tridecadeoxynukleotid, verfahren zu seiner herstellung und verwendung"
US4464359A (en) *	1981-04-10	1984-08-07	Research Corporation	(2'-5')-Oligo (3'-deoxyadenylate) and derivatives thereof
WO1983001451A1 (en) *	1981-10-23	1983-04-28	Molecular Biosystems Inc	Oligonucleotide therapeutic agent and methods of making same
US4393201A (en) *	1981-11-04	1983-07-12	The Wistar Institute	DNA Which codes for glycoprotein of era-strain rabies virus

1984
- 1984-10-10 NZ NZ209840A patent/NZ209840A/xx unknown
- 1984-10-12 GB GB08425799A patent/GB2148302B/en not_active Expired
- 1984-10-15 SE SE8405133A patent/SE466482B/sv not_active IP Right Cessation
- 1984-10-15 AU AU34239/84A patent/AU578625B2/en not_active Expired
- 1984-10-15 PH PH31340A patent/PH21629A/en unknown
- 1984-10-15 LU LU85594A patent/LU85594A1/de unknown
- 1984-10-15 US US06/661,204 patent/US4689320A/en not_active Expired - Lifetime
- 1984-10-16 AT AT0329284A patent/AT392081B/de not_active IP Right Cessation
- 1984-10-16 DK DK493584A patent/DK168061B1/da not_active IP Right Cessation
- 1984-10-16 NL NL8403163A patent/NL8403163A/nl active Search and Examination
- 1984-10-16 IT IT68021/84A patent/IT1179144B/it active
- 1984-10-16 DE DE19843437852 patent/DE3437852A1/de not_active Withdrawn
- 1984-10-16 BE BE0/213837A patent/BE900827A/fr not_active IP Right Cessation
- 1984-10-17 IE IE2668/84A patent/IE57987B1/en not_active IP Right Cessation
- 1984-10-17 FR FR8415930A patent/FR2553420B1/fr not_active Expired
- 1984-10-17 CH CH4975/84A patent/CH667593A5/de not_active IP Right Cessation
- 1984-12-12 MT MT957A patent/MTP957B/xx unknown
1988
- 1988-05-19 SG SG310/88A patent/SG31088G/en unknown

Also Published As

Publication number	Publication date
AT392081B (de)	1991-01-25
AU578625B2 (en)	1988-11-03
SG31088G (en)	1988-09-30
MTP957B (en)	1985-05-27
CH667593A5 (de)	1988-10-31
IE57987B1 (en)	1993-06-02
SE8405133L (sv)	1985-04-18
PH21629A (en)	1987-12-11
IT1179144B (it)	1987-09-16
FR2553420B1 (fr)	1988-04-01
BE900827A (fr)	1985-02-15
DE3437852A1 (de)	1985-05-23
ATA329284A (de)	1990-07-15
NL8403163A (nl)	1985-05-17
AU3423984A (en)	1985-04-26
DK493584D0 (da)	1984-10-16
DK493584A (da)	1985-04-18
IT8468021A1 (it)	1986-04-16
IE842668L (en)	1985-04-17
IT8468021A0 (it)	1984-10-16
SE8405133D0 (sv)	1984-10-15
GB8425799D0 (en)	1984-11-21
US4689320A (en)	1987-08-25
GB2148302B (en)	1987-10-07
GB2148302A (en)	1985-05-30
NZ209840A (en)	1988-11-29
FR2553420A1 (fr)	1985-04-19
SE466482B (sv)	1992-02-24
LU85594A1 (de)	1985-04-02

Legal Events

Date	Code	Title	Description
1994-01-31	B1	Patent granted (law 1993)
2004-11-01	PUP	Patent expired

Publication	Publication Date	Title
US4689320A (en)	1987-08-25	Method for inhibiting propagation of virus and anti-viral agent
US6372427B1 (en)	2002-04-16	Cooperative oligonucleotides
EP0664833B1 (de)	1996-12-27	Therapeutisches anti-hiv oligonukleotid und arzneimittel
KR970005274B1 (ko)	1997-04-15	안티센스 올리고뉴클레오티드에 의한 a형 인플루엔자 바이러스, 안 아아보스트레인(ann arbor strain) h2n2의 억제
US6150339A (en)	2000-11-21	Anti-viral guanosine-rich oligonucleotides
SenGupta et al.	1989	Activation of interferon-regulated, dsRNA-dependent enzymes by human immunodeficiency virus-1 leader RNA
US20150361432A1 (en)	2015-12-17	Modified small interfering rna molecules and methods of use
WO1994008004A9 (en)	1994-06-23	Therapeutic anti-hiv oligonucleotide and pharmaceutical
US8138161B2 (en)	2012-03-20	Modified small interfering RNA molecules and methods of use
Goulaouic et al.	1994	Exogenous nucleosides promote the completion of MoMLV DNA synthesis in G0-arrested Balb c/3T3 fibroblasts
US9084808B2 (en)	2015-07-21	Modified small interfering RNA molecules and methods of use
CA2211877A1 (en)	1996-08-08	Human immunodeficiency virus transcription inhibitors and methods of their use
IE913321A1 (en)	1992-02-25	Compositions and methods for inhibiting growth or¹replication of microbes, viruses and self-replicating¹nucleic acids
KR20230034164A (ko)	2023-03-09	수두-대상포진 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
WO1997038097A1 (en)	1997-10-16	Cooperative oligonucleotides
WO1997033992A1 (en)	1997-09-18	Selected oligonucleotides with anti-cytomegalovirus activity
AU2003236659B2 (en)	2008-04-03	Cooperative oligonucleotides
JP3328682B2 (ja)	2002-09-30	ヘルペスウィルスの増殖阻害方法
KR100231318B1 (ko)	1999-12-01	종양괴사인자 알파 수용체의 c-말단 부분을 갖는 레트로바이러스 벡터 및 이를 이용한 hiv-1 증식 억제 방법
JPH0456804B2 (de)	1992-09-09
JP2003527419A (ja)	2003-09-16	抗ｈｉｖ活性を有する化合物
US20030216334A1 (en)	2003-11-20	Methods for inhibiting/treating hiv infections and aids related symptoms
AU2003236659A1 (en)	2003-09-18	Cooperative oligonucleotides
WO2001049297A1 (en)	2001-07-12	Methods for inhibiting/treating hiv infections and aids related symptoms